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Drug development requires physiologically more appropriate model systems and assays to increase
understanding of drug action and pathological processes in individual humans. Specifically, patient-
derived cells offer great opportunities as representative cellular model systems. Moreover, with novel
label-free cellular assays, it is often possible to investigate complex biological processes in their native
environment. Combining these two offers distinct opportunities for increasing physiological relevance.
Here, we review impedance-based label-free technologies in the context of patient samples, focusing on
commonly used cell types, including fibroblasts, blood components, and stem cells. Applications extend
as far as tissue-on-a-chip models. Thus, applying label-free technologies to patient samples can produce
highly biorelevant data and, with them, unique opportunities for drug development and precision
medicine.Introduction
Two significant challenges to current drug development are the
interindividual variability in drug effectiveness, and lack of trans-
latability of preclinical results. Simultaneously, modern medicine
is shifting towards personalized or precision medicine, which
proposes to use individual characteristics of a specific patient or
subpopulation to tailor drug prescriptions, thereby decreasing
risks of ineffective dosing or adverse effects [1]. Challenges to
achieve this are associated with a generally perceived lack of
understanding of the molecular details of drug action and of
pathological processes in the human individual. This is brought
about to a large degree by insufficient physiological representabil-
ity of the model systems and assays used in drug research. Tradi-
tional drug research has relied on a target-focused approach by
screening compounds in in vitro assays. Such assays traditionally
use reporter systems, for instance radiolabeled or fluorescent
probes, dyes, and reporter gene constructs, all of which are mod-
ifications that can influence target pharmacology (Box 1). In
addition, cellular models and cell systems are often selected based
on habit and technical feasibility rather than on disease relevance,Corresponding author: IJzerman, A.P. (ijzerman@lacdr.leidenuniv.nl)
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1359-6446/ã 2017 The Authors. Published by Elsevier Ltdresulting in physiologically less representative heterologous or
recombinant cells lines. Such renewable in vitro cell sources have
been essential in facilitating drug discovery and have merits for
studying target or drug action in more detail. However, both assay
and model systems are factors that can contribute to an eventual
lack of clinical effectiveness and, thus, to issues experienced in
drug development to date, such as high attrition rates [2]. To fully
comprehend the mechanisms underlying pathologies, drug re-
sponse, and its variation in individuals, functional characteriza-
tion on a physiologically relevant molecular and cellular level is
essential. Hence, the focus is shifting to more physiologically
appropriate cellular models and readout systems. Specifically,
patient-derived cells offer great opportunities when used directly
as a model system. Novel label-free cellular assays are a new type of
phenotypic assay that can result in molecular-level understanding
of complex biological processes in their native environment [1,2].
Applying such assays to human primary cells can increase the
physiological relevance of the results [3–5]. In this review, we
highlight the reach of these possibilities by focusing on the
application of one such label-free cellular assay, based on imped-
ance, to some of the most common types of human primary cells
derived from patient samples.. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
http://dx.doi.org/10.1016/j.drudis.2017.07.015
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BOX 1
Traditional label-based versus label-free assays
Traditional label-based assays follow drug effects and cellular
functions by the chemical attachment of a ‘label’ to the drug
molecule, drug target, or downstream effectors. These can
comprise, for instance, radiolabeled or fluorescent probes or dyes.
Reporter-based assays introduce specifically regulated gene
promoters as biomarkers for specific events. Commonly used
reporter genes involve visually identifiable characteristics, such as
fluorescent and luminescent proteins (Figure I).
Label-free assays do not require any such modifications because
they measure cellular changes by alternative detection means,
without the need to introduce chemical or bioengineered
modifications.
FIGURE I
Traditional label-based assays. Stars highlight where effects are often
measured by introducing labels or reporters. Image constructed using
components from Servier Medical Art by Servier (www.servier.com/
Powerpoint-image-bank).
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The two currently most-used forms of label-free cellular biosensors
are impedance- or optics-based biosensors. Extensive reviews on
the detection principles are provided elsewhere [6–8]. In short, the
ECIS, xCELLigence, and CellKey systems use an electrode array
biosensor to measure impedance changes in a cell monolayer
(Fig. 1). Optical systems, such as the EPIC and BIND, use resonant
waveguide grating to detect dynamic mass redistribution in cells.
Both optical and impedance methods detect a spectrum of cellular
changes, from cell adhesion to life cycle processes, such as prolif-
eration, growth, and death; as well as pathogen infections and
response; cell migration; and signaling, such as receptor signaling
or cell–cell communication [6]. Hence, these label-free assays are
also known as phenotypic assays.
In this review, we focus on impedance-based assays, which are
applicable to a range of samples, are highly versatile and can
integrate many assays into one (Fig. 2). For instance, such assaysrecord a variety of cellular parameters, including proliferation,
adhesion, and cellular morphology, in one combined read-out in
real-time (Fig. 1 and Fig. 2a). This is a particular advantage over
many traditional assays, which often interrogate one aspect only
of a given pathway or a cellular response (e.g., second messenger
accumulation). Impedance-based assays offer the distinct advan-
tage of a direct read-out of drug action in real-time. Although there
are also traditional assays that record specific functions in real-
time (e.g., Ca2+-mobilization assays), impedance measurements
offer the benefits of real-time measurements in both acute (e.g.,
direct receptor signaling) and chronic settings (e.g., cellular pro-
liferation). Besides recording the abovementioned cellular func-
tions, impedance-based label-free assays also provide some
specialist applications, such as electrical stimulation for pore
formation (Fig. 2d) and co-culture without contact (Fig. 2h), al-
though these can require specialized recording or plate equipment
(Fig. 2b,e,h). Overall, impedance-based assays have already been
successfully applied to an extensive list of targets, including im-
portant drug target classes, such as G-protein-coupled receptors
(GPCRs) [6,9], nuclear receptors [10], and receptor tyrosine kinases
[11]. Applications extend as far as toxicity screens on cardiac
function [12] and migration of cancer cells in 3D cultures [13]
(Fig. 2b,e). Furthermore, almost any cell type can be studied.
Examples include standard recombinant cell lines, primary and
stem cells, both adherent as well as suspension cell types [6,9,14]
(Table 1). This is because, in comparison to many traditional
assays, label-free technologies offer a sensitive, less-invasive detec-
tion methodology that monitors drug effects on a whole cell.
Furthermore, without the need for tagging, labeling, or recombi-
nant expression, cellular functions can be studied in a more
physiological context, including a vast amount of endogenously
expressed targets and pathways. Simultaneously, sensitivity is
often high enough to distinguish subtle changes in mechanisms
of action in, for example, GPCR signaling bias [6,14]. Receptors are
linked to various downstream signaling pathways, a feature
termed ‘signaling pluridimensionality’. Ligands can be biased
towards one or some particular downstream pathways, potentially
resulting in different pharmacological effects. For instance, closely
related agonists of the b2-adrenergic receptor induce subtly yet
distinctly different response signatures as a consequence of such
bias [15,16].
Hence, as several reviews have already summarized, label-free
technologies can offer distinct advantages for drug development.
They capture compound action in a dynamic time-resolved man-
ner, allow for the identification of leads independent of prior
assumptions of signaling pathways, and enable the use of more-
native systems at higher throughput. As a cell phenotypic screen,
they can be used for target identification, compound screening,
lead selection, investigating the mechanism of action, and test-
ing drug safety and toxicity [14,17]. In this review, we particularly
focus on applications involving patient cells. This offers oppor-
tunities for both drug development and precision medicine re-
search by sensitively detecting an extensive variety of
pharmacological effects under minimally invasive conditions
in a clinically relevant endogenous context of primary cells,
and even patient samples. Nowadays, such samples are increas-
ingly available to support research, for instance by their system-
atic collection in biobanks.www.drugdiscoverytoday.com 1809
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FIGURE 1
Principle of impedance-based label-free cellular assays. Cell attachment to gold electrodes generates impedance by changing the local ionic environment at the
electrode–solution interface. Relative changes in impedance (Z) are recorded in real-time. (a) Before the seeding of cells, baseline impedance is Z0. (b) As cells
adhere to the electrodes, impedance increases proportionally. (c) Changes in cell number, adhesion, viability, and morphology are directly reflected in the
impedance profile. Impedance-based label-free cellular assays can detect a range of cellular events, including cell proliferation, division, growth, death,
migration, and signaling. All these parameters can, in turn, be affected by drugs. For instance, depending on the moment of drug treatment, drugs can result in
response A by initiating receptor signaling or drug response B by decreasing overall proliferation.
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Over the past decades, numerous biobanks have emerged to
support medical research by the programmed storage of biological
material and corresponding data. These biomaterials include
tissues, (stem) cells, blood, and serum, all of which have had a
critical role in medical research. These materials are actively used
from translational and personalized medicine research to target
and drug discovery [18,19]. For human physiology, primaryFIGURE 2
Typical applications of impedance-based label-free cellular assays. (a) General label
such as adherence, proliferation, viability, and morphology. Additional specialize
through a porous membrane, xCELLigence); (c) measure barrier functionality, for in
increase cellular permeability (ECIS); and (e) measure (cardio)-myocyte contractilit
assays are also applicable to suspension cells and capable of monitoring interactio
another type of target cell or (h) cell–cell communication without any cellular c
1810 www.drugdiscoverytoday.comhuman cells are considered a better model system than the more
traditional cellular models, such as rodent, recombinant, or
immortalized nontissue specific human cell lines, and even better
than in vivo rodent models [20–22]. Although the abovemen-
tioned cellular models have merits, for instance ease of use or to
attain initial understanding of pathways, their physiological
relevance is questioned increasingly. In recombinant cell lines,
target overexpression, differences in intracellular metabolic-free cellular assay formats are capable of monitoring many cellular functions,
d assay applications exist, for instance, to (b) monitor cell migration (e.g.,
stance, in a wound scratch assay; (d) apply electrical impulses, for example, to
y (xCELLigence CARDIO system). (f) Besides adherent cells, label-free cellular
ns between two cell types, for instance by (g) cytotoxicity of effector cells on
ontact (xCELLigence co-culture set-up).
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TABLE 1
Application examples of impedance-based label-free cellular technology to patient samples and stem cell related types
Type Subtype Technology Material source Refs
Blood components Antibodies xCELLigence Patients with type I diabetes or type II diabetes and healthy controls [37]
PBMCs xCELLigence From healthy volunteers but tested on patient material [32,33]
Plasma and cells therein ECIS Healthy volunteers versus trauma patients [35]
ECIS Patients with Hantavirus cardiopulmonary syndrome [36]
Monocytes ECIS Patients with peripheral vascular disease and abdominal aortic
aneurysm
[31]
Neutrophils ECIS Critically ill patients with sepsis [34]
Serum ECIS Patients with scleroderma [27]
Cancer cells and
related cells
gd T cells xCELLigence Healthy volunteers and patients with B-cell ALL [60]
Glioblastoma cells xCELLigence Paired tumoral and peritumoral tissue samples from patients with
glioblastoma
[54]
Malignant melanoma cells xCELLigence Malignant melanoma of the ciliary body from a female patient [55]
Malignant pleural effusions xCELLigence Patients with solid tumors [59]
Mesenchymal chondrosarcoma cells xCELLigence Newly established cell line from patient [56]
Mononuclear cells xCELLigence Normal controls and patients with breast cancer [61]
Myxofibrosarcoma cells xCELLigence Patient with myxofibrosarcoma [58]
Non-small cell lung carcinoma cells xCELLigence Patient with non-small cell lung carcinoma [57]
Normal and neoplastic mammary cells xCELLigence Patient-derived primary human breast cancer epithelial cells [8]
Ovarian cancer cells xCELLigence Patient with serous ovarian cancer and patient with endometrioid
peritoneal cancer
[53]
Chondrocytes Chondrocytes and cartilage tissue xCELLigence Patients with OA [32]
Fibroblasts Benign prostatic hyperplasia xCELLigence Patients with benign prostatic hyperplasia [26]
Dermal ECIS Patients with scleroderma and normal controls [27]
Orbital ECIS Patients with or without Graves’ disease [24]
Synovial xCELLigence Patients with RA or OA [28–30]
iPSCs and similar
stem cell types
Adipose stromal/stem cells ECIS Healthy human donors of varying age groups [51]
xCELLigence Female patients undergoing liposuction, model for obesity [52]
iPSC cardiomyocytes xCELLigence Healthy human donors or commercial from Cellular Dynamicsa [12,43–45]
iPSC retinal pigment epithelium ECIS Patient with AMD and unaffected sibling [47]
Mesenchymal stromal/stem cells ECIS and
xCELLigence
From bone marrow (three donors) and adipose tissue (two donors) [48]
xCELLigence From endometrial lining of the uterus of premenopausal women [49]
xCELLigence Healthy human donors [50]
xCELLigence Patients with OA [33]
Myoblasts Skeletal muscle myoblasts
and myotubes
xCELLigence Patients with chronic heart failure and age- and gender-matched
healthy donors
[62,63]
awww.cellulardynamics.com/products/cardiomyocytes.html.
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responses [5]. Well-established cell lines derived from a patient
with a particular disease can be more representative of that
specific pathological condition. However, these are generally
immortalized cell lines derived from one particular patient sam-
ple a long time ago. Prolonged cell culture frequently leads to
problems, such as contamination or genotypic and phenotypic
instability. These issues unfortunately contribute to irreproduc-
ibility in preclinical research, which is an increasingly well-rec-
ognized problem [23].
In general, primary cells express signaling pathways and retain
many cellular functions that are seen in vivo, thus providing a more
relevant context. Tissue or cell samples from healthy or patient
volunteers are even more representative of (patho)physiology and
closer to the situation in the clinic.
Application to patient samples and primary human
cells
Many patient-related biomaterials can and have already been
studied using impedance-based label-free technologies, of
which some prominent examples are discussed here. The sample
types most commonly studied include fibroblasts and bloodcomponents, but applications also extend to endothelial, epithe-
lial, and stem cells (Table 1). In these examples, label-free imped-
ance-based assays are used to monitor a range of cellular effects,
including specific functions, such as migration, epithelial barrier
function, or cardiomyocyte beating (Fig. 2). Overall, the highlight-
ed examples show that impedance-based label-free technology is
highly versatile with an extensive range of applications.
Fibroblasts
The earliest applications of label-free assays to fibroblasts date
back more than two decades. In one early example, by compar-
ing morphological changes of orbital fibroblasts from patients
with and without Graves’ disease versus dermal fibroblasts, pros-
taglandin E2 was shown to have a significant role in Graves’
disease pathology (Fig. 2a). The authors chose ECIS over tradi-
tional light microscopy after testing both methodologies head to
head, because ECIS offered insight into the subtle, rapid cellular
changes, especially into the underlying kinetics, of this disease
[24].
Since then, label-free cellular assays have been applied to other
types of fibroblast. Fibroblasts are in fact the most common cell
type in human connective tissue and can often retain memory ofwww.drugdiscoverytoday.com 1811
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blast types (Table 1). They are also among the most commonly
used clinical and biobanked samples [25].
For instance, Nolte et al. demonstrated a potential strategy
against hyperproliferating fibroblasts by treating fibroblasts from
patients with benign prostatic hyperplasia with small interfering
(si)RNA against the transcription factor serum response factor.
Effects on cell proliferation and growth inhibition were detected
with the xCELLigence (Fig. 2a) [26]. Another notable study in-
volved dermal fibroblasts and sera from patients with scleroderma,
which is discussed below [27].
Finally, in a clinically relevant setting, synovial fibroblasts from
patients with rheumatoid arthritis (RA) or osteoarthritis (OA)
obtained during knee surgery were investigated. In the most recent
studies, Lowin et al. used xCELLigence to show that the endocan-
nabinoid system is involved in regulating inflammatory effects in
RA [28]. This suggested a potential treatment for RA with synthetic
cannabinoids, demonstrated in a later study [29]. Similar studies
showed further contributors to the pathogenesis of RA that modify
the cellular functions and adhesion of synovial fibroblasts, the
most recent of which are included in Table 1 [30]. The relevance
and implications of these findings for potential treatment options
are of translational value because the cells were obtained from
patients with the disease.
Blood cells
Blood is an easily obtained patient material and, thus, is often
biobanked [25]. Hence, various types of blood components or cells
are used in medical research and have been investigated using
impedance-based label-free cellular assays.
Several studies involving monocytes have been published. In-
terestingly, monocytes are often measured indirectly by quantify-
ing their effect on another cell type. A layer of adherent target cells
is grown on the electrodes, after which they are exposed to the
effector cells, here monocytes, which induce cytotoxicity in the
target cells, for instance (Fig. 2g). Lee et al. used ECIS to reveal
differences between patients with peripheral vascular disease and
with abdominal aortic aneurysm to find better methods for tar-
geted therapy. Monocytes of patients with peripheral vascular
disease induced higher endothelial barrier dysfunction [31] com-
pared with those from patients with abdominal aortic aneurysms.
Another particularly useful type of blood cell are peripheral
blood-derived mononuclear cells (PBMCs). Hopper et al. showed
that PBMCs enhanced osteoarthritic human chondrocyte migra-
tion, which could be the basis for a treatment strategy for OA.
PBMCs were derived from healthy volunteers, whereas chondro-
cytes and cartilage tissue explants were from patients undergoing
total knee replacement. Here, the migration and chemokinetic
potential of the cells were measured using a specialized migration
assay format of the xCELLigence (Fig. 2b) [32]. Later, it was shown
that PBMCs also enhanced the migration and chondrogenic dif-
ferentiation of multipotent mesenchymal stromal cells (MSCs)
from knees of patients with OA [33].
Other types of blood component have also been assayed using
label-free technology, although most studies again relied on an
indirect measurement through effects on another cell type. For
instance, neutrophils from critically ill patients with sepsis were
found to reduce endothelial barrier integrity to a greater extent1812 www.drugdiscoverytoday.comthan untreated normal neutrophils in an ECIS assay [34]. Human
serum was also used in some studies. In an early example by Huang
et al., ECIS was used to demonstrate differences in micromotions of
dermal fibroblasts from patients with scleroderma and from nor-
mal controls, as well as the effect of sera from patients on fibroblast
behavior [27]. Rahbar et al. measured the effects of plasma samples
from healthy volunteers and severely injured trauma patients on
human endothelial cells using ECIS. Material of patients with low
plasma colloid osmotic pressure caused an increase in cell perme-
ability [35]. In a similar manner, plasma samples of patients with
Hantavirus cardiopulmonary syndrome were shown to induce the
loss of cell–cell adhesion in epithelial and endothelial cells in ECIS
[36]. Finally, Jackson et al. used xCELLigence to demonstrate that
anticalcium channel autoantibodies from patients with type 1
diabetes mellitus inhibited the adherence of Rat insulinoma cells,
while antibodies from patients with type 2 diabetes mellitus and
from healthy controls did not [37].
The reason why all these blood components are measured
indirectly is twofold. On the one hand, studying their effect on
the function of other cell types provides more physiological con-
text. On the other hand, many of the cell types involved are
suspension cells. Label-free technology was long deemed incom-
patible with suspension cells, because the detection mechanism
positioned at the bottom of the well requires cells to adhere [7].
However, several studies demonstrated that suspension cells are
also amenable to label-free technologies using either optical or
impedance-based biosensors. Interestingly, impedance-based
assays appear less susceptible to decreased cellular adherence than
do optical biosensors [7] and, hence, are potentially applicable to
an broader range of cell types. Examples include various types of
blood cell, one notably involving personal cell lines. For instance,
CellKey was used to directly measure GPCR signaling in mono-
cytes, neutrophils, and PBMCs, although these were not patient
material [38,39]. xCELLigence was applied to lymphoblastoid cell
lines (LCLs) from participants of The Netherlands Twin Register to
show effects of single nucleotide polymorphisms on GPCR signal-
ing [9,40]. On these occasions, increased cell densities and usage of
adherence-mediating agents were sufficient to allow measure-
ments (Fig. 2f). LCLs are a preferred choice for storing genetic
material, including in biobanks of renowned consortia, such as the
International HapMap project [25,41].
iPSC and common stem cell types
Stem cells carry great promise for rendering physiologically more
relevant cell models, in particular induced pluripotent stem cells
(iPSCs). By reprogramming of fibroblasts into a pluripotent state,
for example, iPSCs can be derived that maintain the disease
genotype and phenotype indefinitely. These iPSCs then provide
a source of models for an expansive range of adult differentiated
cells, possibly even for each individual patient, which has the
potential to personalize drug discovery [42]. Many of the cell types
derived from such iPSCs can be investigated using label-free tech-
nology. A specific type of application has been developed for
xCELLigence, namely a cardiomyocyte-based biosensor. Safety
pharmacology studies that evaluate potential cardiac (adverse)
effects of drug candidates are an essential part of drug develop-
ment. The xCELLigence RTCA Cardio System detects the beating
rhythm of cardiomyocytes (Fig. 2e) and has been applied to
Drug Discovery Today Volume 22, Number 12 December 2017 REVIEWS
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sions to investigate risks of drug-induced arrhythmia and general
cardiotoxicity, of which the most recent publications are listed in
Table 1 [12,43–45]. Rhythmic beating is essential for cardiomyo-
cyte function, but has traditionally been hard to investigate in
simple in vitro assays. Phenotypic measurements of native cellular
systems are more suited for this [46]. The xCELLigence Cardio
System capturing cardiac beating was the most sensitive of various
tests for detecting compounds with known clinical cardiac risk
[43], and can be used to evaluate potential clinical drug candidates
[12].
Another stem cell-based study involved iPSC-derived retinal
pigment epithelium (RPE) as a disease model-on-a-chip of age-
related macular degeneration (AMD). In general, epithelial and
endothelial cells are often studied using label-free technology, and
some specific assay formats related to formation and disruption of
monolayers have been developed for these (e.g., barrier function,
Fig. 2c). Here, RPE cells from a patient with inherited AMD and an
unaffected sibling were examined using an ECIS electrical wound-
healing assay. Real-time monitoring over a 25-day period demon-
strated the establishment and maturation of RPE layers on the
microelectrode arrays, in which spatially controlled damage to the
cell layer was introduced to mimic AMD. Thus, label-free technol-
ogy can also be used to measure long-term effects and is suited for
tissue-on-a-chip technology. This offers translational value by
enabling real-time, quantitative, and reproducible patient-specific
studies [47].
Another stem cell type of interest are MSCs, which are attractive
candidates for tissue engineering because of their wide meso-
dermal differentiation potential. Angstmann et al. compared ECIS
and xCELLigence in a search for standardized quality control
assays to monitor differentiation and high-throughput screening
that is both non-invasive and time-resolved. The authors studied
MSCs isolated from two different tissues of various donors, namely
bone marrow and adipose tissue. Impedance measurements were
used to discriminate osteogenic from adipogenic differentiation,
which showed modulating effects of extracellular matrix compo-
nents [48]. Label-free assays were also used to establish culture
conditions for expansion of endometrial MSC (eMSC) isolated
from endometrial lining of the uterus of premenopausal women
[49] or to test MSC labeling by a new type of nanoparticle [50].
In another instance, ECIS was used to monitor proliferation and
osteogenic differentiation of human adipose stem cells (hASC)
from donor populations of different ages. This assay could be used
to predict the osteogenic potential for patient-specific bone tissue
engineering [51]. Finally, Berger et al. studied molecular mecha-
nisms in human obesity in hASCs from liposuctions of female
patients. By studying lipid uptake and adipocyte differentiation
with xCELLigence, the authors identified several dysregulated
adipocyte-specific genes involved in fatty acid storage or cell
adhesion [52].
Other cell types
Label-free assays are suited for almost any cell type and have been
applied to numerous others besides the most commonly bio-
banked samples highlighted above.
A further category of particular interest are cancer and related
cell types. Here, impedance-based cellular assays are often used tomeasure migratory and invasive properties (e.g., Fig. 2b), which are
key characteristics of any (metastatic) cancer type. For instance,
xCELLigence was used to monitor the motility of primary human
normal mammary cells versus patient-derived breast cancer epi-
thelial cells [8], migration in various ovarian cancer patient sam-
ples [53] and proliferation and response to kinase inhibitors in
glioblastoma samples from patients [54]. Others have evaluated
(potential) treatment options on a patient’s malignant melanoma
cells [55] and on a newly established mesenchymal chondrosar-
coma cell line from a patient [56]. Two other publications used
xCELLigence for characterization of newly established cell lines
from patient samples, offsetting them against parental tumor
tissue or traditionally used carcinoma cell lines [57,58]. Finally,
Ruiz et al. applied xCELLigence to patients’ own cancer cells for the
in vitro selection of the most promising treatment, in this case for
human carcinoma cells from malignant pleural effusions [59]. This
is an illustrative example of possible applications in precision
medicine.
Impedance-based technologies are also suited to test potential
cell-based therapies (Fig. 2g). Seidel et al. demonstrated the thera-
peutic potential of gd T cells for antibody-based immunotherapy
in pediatric patients with B-lineage acute lymphoblastic leukemia
(ALL). gd T cells were derived from healthy blood donors as well as
from a patient with common ALL. xCELLigence was used to
measure gd T cell lysis in a breast adenocarcinoma cell line in
real-time, and outperformed the traditional endpoint assay [60]. In
a similar manner, others have studied the ability of mononuclear
cells from normal patients and those with breast cancer to kill
different breast cancer cell lines in the presence or absence of
trastuzumab [61].
Myoblasts from muscle biopsy samples are another cell type of
interest. In a recent example, Sente et al. studied pathological
mechanisms of heart failure. Using xCELLigence, they observed
myoblast adiponectin signaling, differentiation, proliferation, and
viability in primary myoblasts and myotubes from patients with
chronic heart failure and age- and gender-matched healthy donors
[62,63].
From drug discovery to precision medicine
As a result of their versatility, label-free assays and patient cells,
when combined, can be utilized at various stages of medicines
research. As a cell-phenotypic screen, label-free assays are well
suited for target identification, compound screening, and lead
selection. Likewise, they allow the investigation of mechanisms
of action and the testing of drug efficacy and safety [14,17]. In this
review, we have provided typical examples involving patient cells,
which offer increased physiological context. Given that such
patient samples are often in limited supply, this set-up is not
regularly used for screening drug candidates, for example, but
rather for understanding disease mechanisms and testing poten-
tial treatments. This was done by Lowin et al. in the context of RA
to identify drug targets, subsequently test compounds, and define
possible treatments [28,41]. In a more integrated approach, the
combination of patient cells and label-free assays resulted in tissue-
on-a-chip technology, as demonstrated by Gamal et al. [47]. It is to
be expected that the advent of stem cell technology will radically
change the availability of patient-derived materials [42,64], which
would allow further integration of label-free assays. This would bewww.drugdiscoverytoday.com 1813
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if patient-derived material can be made available readily, on
demand, and in larger quantities. However, the question arises
whether label-free technologies can be developed that take the
three-dimensionality of advanced cellular models and organoids
into account [65–67]. In drug safety and toxicity research, iPSC-
derived cardiomyocytes can be used in a label-free setting to
evaluate potential cardiac (adverse) effects of drug candidates
[12,43]. Finally, the combination of patient cells and label-free
technology can be used for clinical compound selection, for
instance by measuring patient cell responses in vitro as means of
selecting the most promising treatment. This has been demon-
strated by profiling drug treatment responses of patient-derived
malignant pleural effusions in a study by Ruiz et al. [59], with the
aim to provide drug treatment of cancer in a personalized manner.1814 www.drugdiscoverytoday.comConcluding remarks
Physiologically more-appropriate cellular models and readout
systems are needed to increase representability and translational
value. Patient-derived cells can provide pathological and physio-
logical context, and biobanking has increased the availability of
human primary samples for research. Label-free impedance-based
assays can and have been applied to a range of such samples. These
assays increase the physiological representability by omitting
reporter-based modifications and measuring physiological cell
function in real-time. Thus, combining label-free assays with
human primary samples offers a uniquely biorelevant set-up for
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